TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the plasma concentration time curve of danoprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Level as measured by SF-36
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Pain Level as measured by LANSS survey
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Pain Level as measured by Phantom Limb Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: RPNI tissue degeneration measured by pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RPNI electrode migration assessed by changes recording in efficacy and ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in overjet reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Cesarean Delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Puerperal Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Emotional reactivity (positive and negative affect)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Life Quality at 24 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline Blood Pressure at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Risk of Fall at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage failure conditioned by assigned duration of antibiotic therapy
Endpoint domain: Adverse events/effects
Primary endpoint: AUC for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in non-high-density lipoprotein cholesterol (non-HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Days of Mechanical Ventilatory Support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for Manual Removal of Placenta
Endpoint domain: Adverse events/effects
Primary endpoint: concentration of scalp hair cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Chronic breast pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of co-morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physician's Global Assessment (PGA) Ratings of Good or Better
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toxicity Effect
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Markedly Abnormal Values of Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Standardized Uptake Value (SUV) of the internal carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Target-to-Background Ratio (TBR) of the internal carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Endothelial Progenitor Cells Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12 Month Retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Vasculature of the flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Facial accessibility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bone characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Biochemical measures of brain-derived neurotrophic factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in blood potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Assessment of diabetic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient compliance to Ketosteril
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite of Death, Myocardial infarction and Target Lesion Revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: Longitudinal change in residual glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Balance error scoring system test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up & Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic efficiency of ctDNA and exosome detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall analgesic effect measured by total pain relief score (TOPAR8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of pain intensity difference over 8 hours post dose (SPID8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's global evaluation at 8 and 24 hours post dose
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of mitral regurgitation (regurgitant volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent COAT-platelet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Static Physician Global Assessment (sPGA) Score Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area Severity Index (PASI) 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area Severity Index (PASI) 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of NVP, INH, RIF, and LPV/r
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of repeated skin testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite of death and/or need for mechanical ventilation and/or admission to ICU
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of a clinical manifest cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: assessment of pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Mouth Opening change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of estimated Area Under the Curve (0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 4-hour post-prandial TG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hip muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24 Hour Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Protein/Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in craniofacial suture width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain after venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time course of glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Abundance of Staphylococcus Aureus in the Nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Abundance of Staphylococcus Aureus in the Throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Abundance of Gram Negative Bacteria on the Subclavian Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the Abundance of Gram Negative Bacteria on the Femoral Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevention of overweight/obesity in offspring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of overweight/obesity in mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in overnight mean glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in PROMIS Pain interference
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: salivary miRNA profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of PA-824
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing a Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PR-OCTA Measure of Non-Perfusion Areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-PR-OCTA Measure of Retinal Non-Perfusion Areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-PR-OCTA Retinal Neovascularization Areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural OCT Cyst Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural OCT Retinal Thickening Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathologic response rates (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: level of triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Binocular Distance Corrected Visual Acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of functions, activity and participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Enrollment and retention rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Ventricular Tachycardia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Burden of Ventricular Tachycardia Recurrence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best objective response to nab-paclitaxel treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diastolic Blood Pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate (Bpm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of p.Gly648Ser and p.Arg854X
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with improvement in mEASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Serious Atrial Fibrillation Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Freedom From Symptomatic Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating anti-beta2-glycoprotein I antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flow-mediated arterial dilatation (FMAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitrite serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measures of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Vascular inflammation (Standard Uptake Value) - Carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular inflammation (Tissue to Background Ratio TBR) - Carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular inflammation (Standard Uptake Value) - Aortic artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular inflammation (Tissue to Background Ratio TBR) - Aortic artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Time Per Day When Cellular Connection Was Established
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of latent COVID-19 infections
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Bexarotene Oral Capsules
Endpoint domain: Adverse events/effects
Primary endpoint: WOSI-Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in frequency of substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Periapical index (PAI) for retreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal bone levels (MBL) for implant insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver frailty index (LFI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in six minute walk test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in poor parental knowledge regarding children's oral health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in poor parental behavior regarding children's oral health
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Anti-Cyclic Citrullinated Protein blood test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Modified Citrullinated Vimentin blood test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rheumatoid Factor blood test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of cases of asymptomatic bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Index Subjects Free of Any of Lice 14 Days After Their Last Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cinetic gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 31P metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CR+nCR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Toxic and side effects caused by TACE or radioembolization with Y-90
Endpoint domain: Adverse events/effects
Primary endpoint: treatment limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients who respond to the survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Coronary Artery Calcification (CAC) - Volume Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum observed concentration (Cmax) of BMS-626529
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of BMS-626529
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-626529
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity Level (daily caloric consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Days using Apple Watch
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetics of sorafenib in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Single-dose safety of sorafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with AF episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median overall-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Cmax of rifabutin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who developed at least one stage 2 pressure injury
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of severe primary dysfunction of the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg bone length measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P-cresol removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life Quality Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: deltaTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient/caregiver adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stopping power ratio differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma (peak) drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Clear/Almost Clear (0 or 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Pap test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUCτ of PF-06801591 at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctrough of PF-06801591 at Steady State, at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: S100B protein level (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of a clinically significant anomaly on the MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final diagnostic as established by an expert committee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen Saturation (OS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quantified opioid-consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karitane parenting confidence scale (KPCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant Care Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ages & States questionnaire (ASQ-SE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absenteeism and presentism (functionality at work)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Primary and secondary oxidation products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hospitalisation pattern
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Workforce availability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Absolute change of visceral fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes